Arcturus Therapeutics Holdings Inc. (ARCT)
Largest Insider Buys in Sector
ARCT Stock Price History Chart
ARCT Stock Performance
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with …
Insider Activity of Arcturus Therapeutics Holdings Inc.
Over the last 12 months, insiders at Arcturus Therapeutics Holdings Inc. have bought $0 and sold $3.81M worth of Arcturus Therapeutics Holdings Inc. stock.
On average, over the past 5 years, insiders at Arcturus Therapeutics Holdings Inc. have bought $158,967 and sold $27.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,222 shares for transaction amount of $39,996 was made by Marquet Magda (director) on 2022‑12‑15.
List of Insider Buy and Sell Transactions, Arcturus Therapeutics Holdings Inc.
| 2024-10-15 | Sale | Chief Scientific Officer & COO | 12,000 0.0423% | $20.76 | $249,121 | -14.40% | ||
| 2024-06-12 | Sale | Chief Financial Officer | 50,000 0.1838% | $32.03 | $1.6M | -33.64% | ||
| 2024-06-05 | Sale | Chief Scientific Officer & COO | 114 0.0004% | $45.00 | $5,130 | -53.58% | ||
| 2024-06-03 | Sale | Chief Scientific Officer & COO | 26,000 0.095% | $40.01 | $1.04M | -49.31% | ||
| 2024-03-25 | Sale | Chief Scientific Officer & COO | 17,435 0.0652% | $35.02 | $610,574 | -33.64% | ||
| 2024-03-19 | Sale | Chief Scientific Officer & COO | 8,565 0.033% | $35.01 | $299,839 | -30.08% | ||
| 2023-11-01 | Sale | Chief Scientific Officer & COO | 5,000 0.0187% | $18.72 | $93,602 | +47.26% | ||
| 2023-10-02 | Sale | Chief Scientific Officer & COO | 5,000 0.0188% | $25.61 | $128,062 | +6.78% | ||
| 2023-09-01 | Sale | Chief Scientific Officer & COO | 5,000 0.0187% | $31.45 | $157,264 | -9.92% | ||
| 2023-08-01 | Sale | Chief Scientific Officer & COO | 5,000 0.0184% | $34.91 | $174,550 | -13.40% | ||
| 2023-07-14 | Sale | Chief Scientific Officer & COO | 25,000 0.093% | $35.01 | $875,250 | -12.53% | ||
| 2023-07-14 | Sale | See Remarks | 6,968 0.0259% | $35.00 | $243,880 | -12.53% | ||
| 2023-07-03 | Sale | Chief Scientific Officer & COO | 5,000 0.0189% | $28.75 | $143,750 | +8.03% | ||
| 2023-06-01 | Sale | Chief Scientific Officer & COO | 5,000 0.0189% | $27.16 | $135,800 | +10.95% | ||
| 2023-05-11 | Sale | Chief Scientific Officer & COO | 7,925 0.0279% | $30.24 | $239,652 | -9.63% | ||
| 2023-05-10 | Sale | Chief Scientific Officer & COO | 17,075 0.0656% | $30.00 | $512,250 | -0.37% | ||
| 2023-05-01 | Sale | Chief Scientific Officer & COO | 5,000 0.0187% | $25.93 | $129,650 | +12.25% | ||
| 2023-04-18 | Sale | See Remarks | 6,968 0.0265% | $28.18 | $196,358 | +5.17% | ||
| 2023-04-03 | Sale | Chief Scientific Officer & COO | 5,000 0.0186% | $25.38 | $126,900 | +11.48% | ||
| 2023-03-06 | Sale | Chief Scientific Officer & COO | 5,000 0.0191% | $16.07 | $80,350 | +75.95% |
Insider Historical Profitability
| SASSINE ANDY | Chief Financial Officer | 220526 0.8141% | $16.53 | 4 | 1 | +172.25% |
| Payne Joseph E | President and CEO | 1480097 5.4642% | $16.53 | 3 | 0 | +43.57% |
| FARRELL PETER C | director | 42955 0.1586% | $16.53 | 2 | 0 | +21.56% |
| Marquet Magda | director | 24942 0.0921% | $16.53 | 2 | 0 | +34.48% |
| Kummerfeld Keith C | See Remarks | 950 0.0035% | $16.53 | 2 | 2 | +40.68% |
Institutional Investor Ownership
| Federated Hermes | $158.56M | 17.43 | 4.7M | -0.34% | -$545,047.80 | 0.37 | |
| BlackRock | $92.63M | 10.19 | 2.74M | +14.37% | +$11.64M | <0.01 | |
| State Street | $66.19M | 7.28 | 1.96M | +20.27% | +$11.15M | <0.01 | |
| ARK Investment Management LLC | $57.06M | 6.27 | 1.69M | -17.48% | -$12.09M | 0.2 | |
| The Vanguard Group | $46.87M | 5.15 | 1.39M | -4.83% | -$2.38M | <0.01 |